Decoy Therapeutics (DCOY US): Synthetic Expert Call Transcript (10 Oct 2026)
Decoy Therapeutics faces a severe liquidity runway constraint, holding $8.0 million in total cash as of September 30, 2026—of which $2.5 million...
82 Views
IPO Databook: Decoy Therapeutics (DCOY US) - Oct 2026
Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics...
91 Views
Decoy Therapeutics' (DCOY) Groundbreaking Approach to Drug Development in the AI/ML Era
Meet the CEO. Rick Pierce moved into biotechnology after a 15-year Wall Street career advising biotech and pharmaceutical clients at Lehman Brothers.
119 Views
No more insights